targeted therapy

• 

Immune checkpoint inhibitors for sarcomatoid kidney cancer

By Robert|2021-07-07T10:13:30+00:0015 Mar 2021|Drug treatments|

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive [...]

Read More

Comments Off on Immune checkpoint inhibitors for sarcomatoid kidney cancer

• 

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

By Sophie|2021-03-09T14:39:04+00:002 Mar 2021|Drug treatments|

This Practice Update interview with Dr Monty Pal from City [...]

Read More

Comments Off on Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

• 

Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

By Sophie|2021-03-09T14:30:03+00:001 Mar 2021|Uncategorized|

The Committee for Medicinal Products for Human Use (CHMP) of [...]

Read More

Comments Off on Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer

• 

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

By Sharon Kell|2021-02-09T10:35:27+00:009 Feb 2021|Drug treatments|

The past couple of years has seen a number of [...]

Read More

Comments Off on ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

• 

Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

By Sharon Kell|2021-02-02T09:29:57+00:002 Feb 2021|Drug treatments|

The microbes in the gut (the gut microbiome) are a [...]

Read More

Comments Off on Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer

• 

Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy

By Sharon Kell|2021-01-11T12:00:56+00:0011 Jan 2021|Drug treatments|

This study compared disease outcomes, treatments, and dose reductions in [...]

Read More

Comments Off on Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy

• 

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

By Sharon Kell|2020-10-05T08:52:58+00:005 Oct 2020|Uncategorized|

A recent retrospective study (looking back at the patients’ cases [...]

Read More

Comments Off on Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

• 

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

By Sharon Kell|2020-09-21T09:10:13+00:0021 Sep 2020|Uncategorized|

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]

Read More

Comments Off on ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

• 

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

By Sharon Kell|2020-09-21T08:35:09+00:0021 Sep 2020|Uncategorized|

At the European Society of Medical Oncology (ESMO) Virtual Congress [...]

Read More

Comments Off on ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

• 

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

By Sharon Kell|2020-09-18T08:52:36+00:0018 Sep 2020|Uncategorized|

Over the past 2 years, the use of combination therapies [...]

Read More

Comments Off on ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer